BACKGROUND: Large epidemiological studies indicate that an increased body mass index (BMI) is associated with increased prostate cancer (PCa) mortality. Data indicate that there is no association between elevated metabolic pathway proteins and PCa mortality. There are no published studies evaluating the relation between BMI and metabolic pathways with respect to PCa outcomes with a genomics approach. METHODS: The Decipher Genomic Resource Information Database was queried for patients who had undergone prostatectomy and had BMI information available. These patients came from Thomas Jefferson University (TJU) and Johns Hopkins Medical Institution (JHMI); the latter provided 2 cohorts (I and II). A high-BMI group (30 kg/m 2 ) and a low-BMI group (<25 kg/m 2 )
INTRODUCTION
Prostate cancer (PCa) is the leading cancer diagnosis and the second highest cause of cancer deaths among men in the United States. 1 Despite its prevalence and associated morbidity and mortality, the only established risk factors for the development of PCa are age, race, and family history. 2 The higher incidence of PCa in westernized nations and the higher incidence in Asian Americans versus their Asian counterparts indicate that diet and lifestyle may affect PCa incidence. 2 Despite several large studies examining obesity and PCa, the effect of obesity on PCa incidence remains controversial. [3] [4] [5] [6] The association between a high body mass index (BMI), one standard for quantifying obesity, and PCa mortality is less controversial. Several epidemiological studies indicate that an increased BMI results in higher PCa mortality. [7] [8] [9] [10] [11] [12] Studies examining the relation between aberrant gene expression in pathways related to metabolism, such as blood glucose and lipids, and PCa incidence and mortality have been largely limited by size and regression dilution biases with conflicting results as well. [13] [14] [15] [16] [17] [18] [19] A large prospective study accounting for competing risks and random measurement error demonstrated that metabolic aberrations are associated with a lower risk of a PCa diagnosis, a similar risk for PCa-specific mortality, and a significantly higher risk of death from other causes. 20 Despite multiple epidemiological studies examining BMI, metabolic pathway gene expression, and PCa, data on aberrant metabolism and PCa outcomes are lacking.
Because of the paucity of data in this field and the controversy regarding the relation between the abnormal expression of metabolic pathway genes and PCa outcomes, we used a novel biomarker platform to evaluate the effect of metabolic gene expression on PCa outcomes. We hypothesized that men with higher metabolic derangement would have a more aggressive PCa phenotype and increased mortality.
MATERIALS AND METHODS

Study Cohort
The Decipher Genomic Resource Information Database is a global RNA expression database and cloud-based analytics platform in urologic oncology. It currently consists of RNA expression profiles of biopsy and radical prostatectomy PCa patients from both retrospective and prospective patient cohorts. The Decipher Genomic Resource Information Database was queried for patients who had undergone prostatectomy and had BMI information available. 21 This search yielded 3 cohorts totaling 477 patients. Two of these cohorts (I [GSE79956] and II) included patients from Johns Hopkins Medical Institution (JHMI), and 1 of these cohorts included patients from Thomas Jefferson University (TJU [GSE72291]). The JHMI I and TJU cohorts comprised patients who had undergone surgery from 1990 to 2010 and had outcome information (metastasis and time to metastasis) available. The JHMI II cohort comprised patients who had undergone surgery from 2001 to 2009 and did not have outcome information available. Institutional review boards at JHMI and TJU approved the research protocol under which the data were collected. 22, 23 Specimen selection and processing have been described previously.
22,23
Metabolic Pathways Analysis
We a priori selected and investigated 6 metabolic category pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG): glycolysis and gluconeogenesis; citrate cycle; D-glutamine and D-glutamate metabolism; valine, leucine, and isoleucine degradation; methane metabolism; and glycine, serine, and threonine metabolism (Table 1) . These pathways were selected because of the potential influence of obesity and metabolic derangement on their gene expression. [24] [25] [26] KLK3 expression was also assessed according to the BMI category because low androgen receptor levels are associated with obesity. 27 Decipher Score
Decipher is a 22-gene biomarker that has been developed and validated to aid in predicting metastasis and PCaspecific mortality among patients who undergo radical prostatectomy. 23, [28] [29] [30] The expression values for the 22 biomarkers that constitute Decipher were extracted from the normalized data matrix and entered into the random forest machine learning model, which was locked with defined tuning and weighting parameters described previously. 28 The Decipher score readout is a continuous score between 0 and 1, with higher scores indicating a greater risk of developing metastasis. Decipher scores were categorized into low-risk (<0.45), intermediate-risk (0.45-0.60), and high-risk groups (>0.60) with previously established and validated cut points. 23, 31, 32 Statistical Analysis All statistical tests were 2-sided, and analyses were performed with R version 3.1 (R Foundation, Vienna, Austria). For descriptive statistics, Fisher's exact test and an analysis-of-variance F test were used to compare the statistical significance of differences in categorical and continuous clinicopathological variables, respectively. The correlation between BMI categories and the Decipher score 28 was computed with Spearman's rank correlation. The KaplanMeier method was used to study the association of BMI with the time to metastasis and overall survival. In analyses that considered an association of the BMI or gene signature (or signatures) with oncological outcomes, only the JHMI I and TJU cohorts were included because of a lack of available outcomes for the JHMI II cohort.
A high-BMI group (30 kg/m 2 ) and a low-BMI group (<25 kg/m 2 ) were identified, and genomic data were interrogated for differentially expressed genes with an interquartile range (IQR) filter and a Wilcoxon test. The IQR filter method removed genes with consistently low-intensity values and low variance across all samples with a prespecified IQR threshold. Genes were also tested for significant interactions with BMI (as a continuous variable) in predicting metastasis with the Cox model. The differential expression and interaction analyses were conducted for each institutional cohort individually and also for pooled data. In pooled analyses, expression data were adjusted for a batch effect with ComBat from the sva R package. 33 P values were adjusted for multiple testing with the Benjamini-Hochberg false-discovery rate method.
A heat-map analysis of metabolic genes in each of the cohorts revealed certain genes that consistently clustered together. Specifically, there were 2 consistent groups of genes with opposite regulation of expression, and this suggested them to be the core upregulated and downregulated genes of the metabolic pathways. On the basis of these observations, metabolic activity was summarized as a metabolic score, which was calculated as the difference of the means of 2 consistently clustering subsets of the metabolic genes. Clinical characteristics were interrogated for associations with this metabolic score with a Wilcoxon or Kruskal-Wallis test.
RESULTS
Patient Characteristics
The majority of the patients had Gleason score 7 disease (3 1 4, 39.4%; 4 1 3, 21.6%) and extraprostatic extension (65.6%); 23.1% of the patients had seminal vesicle invasion, and 12.2% presented with lymph node involvement. Patient characteristics stratified by BMI are delineated in Table 2 , with a significantly higher percentage of positive surgical margins in the group with a BMI 30 kg/m 2 (P < .001). The preoperative prostatespecific antigen level, Gleason score (4 1 3 and greater), extraprostatic extension, and seminal vesicle invasion were associated with Decipher score in the multivariate analysis (all P values .02; , and 0.2% had a BMI < 18.5 kg/m 2 . The median follow-up time for the censored patients in our cohort was 9.0 years (IQR, 6.0-13.0 years). Among the 477 selected patients, 75 patients died, and 118 patients experienced metastasis during the study follow-up.
BMI Is Not Associated With the Decipher Score or Risk Category
Fisher's exact test was used to determine whether BMI was associated with Decipher risk categories (low, < 0.45; intermediate, 0.45-0.60; high, > 0.6). There was no association between BMI and the Decipher risk category (P 5 .68; Fig. 1A ). Furthermore, no statistically significant correlation was found between BMI categories and the Decipher score as a continuous variable (r 5 0.04; 95% confidence interval, -0.05 to 0.14; P 5 .34; Fig. 1B ). 
BMI Is Not Associated With PCa Clinical Outcomes in a Prostatectomy Patient Population
To investigate the role of BMI in PCa outcomes, KaplanMeier curves were generated for the rate of metastasis and overall survival. Stratifying the patients by BMI revealed that BMI was not associated with the rate of metastasis or overall survival ( Fig. 2A,B) . In addition, we observed no significant difference in metastasis-free survival rates among BMI categories within different Decipher risk groups (Supporting Fig. 1 [see online supporting information]). In an exploratory analysis, we studied the impact of BMI on outcomes according to prostate-specific antigen levels. Our analysis demonstrated no significant interaction between BMI and levels of prostate-specific antigen in predicting metastasis (interaction P 5 .58; data not shown)
BMI Was Not Found to Be Associated With Altered Gene Expression
Differential expression and interaction analyses were performed to assess gene expression associated with BMI. Initially, we restricted our analysis to the 204 genes in the 6 a priori KEGG metabolic pathways. After adjustments for multiple testing, none of these genes were significant in differential expression or interaction analysis. Next, we performed unbiased differential expression and interaction analyses. No genes were found to be significantly associated with BMI in any cohort when the selected 0.25 IQR threshold was used. We note that when the analysis was restricted to the JHMI I cohort and a higher 0.75 IQR threshold was used (and, therefore, the number of genes adjusted for multiple testing was decreased), significance was attained for 2 genes, FOLH1 and FOLH1B. However, varying the IQR threshold did not result in significantly differentially expressed genes in the other cohorts (JHMI II and TJU) or the pooled analysis (data not shown). In an unbiased interaction analysis, no genes were found to have a significant interaction with BMI in the prediction of metastasis. These results were robust to variations in the IQR threshold and cohort.
Next, we examined significance before adjustments for multiple testing. Although many genes were significantly differentially expressed before adjustments, no genes were significantly differentially expressed in all 3 cohorts. In an interaction analysis, 2 genes, AC129492.1 and AC133106.2, were consistent and significant in both the JHMI I cohort and the TJU cohort (the JHMI II cohort did not have the metastasis status annotated and, therefore, was excluded from the interaction analysis).
Four heat maps of metabolic gene expression were produced with the corresponding patient BMI category, Gleason score, and metastatic disease status: 1 for each cohort and 1 for the pooled cohort (Fig. 3A-D) . A metabolic score was calculated as the difference in means between 2 groups of consistently clustering genes from the metabolic pathways (see the Materials and Methods section). The metabolic score was significantly correlated with metastasis in the pooled cohort (P 5 .009) and the JHMI I cohort (P 5 .003) but was not significantly correlated with BMI in any cohort. Finally, in the pooled cohort, we found no statistically significant association between BMI and KLK3 expression (adjusted P 5 .06).
DISCUSSION
This is the first study to our knowledge that has performed a genomic assessment of BMI and metabolic markers with PCa outcomes. In contrast to prior epidemiological studies, 13 metabolic derangement was found to be significantly correlated with an increased risk of PCa metastases. It is important to note that previous studies looked at only a handful of metabolic markers in large patient cohorts. [13] [14] [15] [16] [17] [18] [19] This study evaluated a more comprehensive platform for aberrant metabolic pathway expression, and this may explain the discrepancy. Furthermore, it is important to note that the genomics influenced a clinical outcome (ie, metastases) that was not associated with the more traditional clinical assessment of BMI.
Initially, the genomic analysis did not reveal any significant associations between gene expression and BMI. Raising the IQR threshold and restricting the analysis to the JHMI I cohort allowed 2 genes, FOLH1 and FOLH1B, to attain significance. Although FOLH1 has known diagnostic and prognostic relevance in PCa, 34, 35 neither gene was found to be significantly differentially expressed in either the JHMI II or TJU data set. In an interaction analysis before adjustments, AC129492.1 and AC133106.2 were consistent and significant in both the JHMI I and TJU cohorts. However, a literature search reveals no known role for these genes in PCa.
Some of the limitations of this study include that it is a retrospective analysis of a specific patient cohort of men after prostatectomy. This may have resulted in a patient selection bias for those who are fit for general anesthesia and do not have significant comorbidities that may be found in men with more severe degrees of obesity. Obesity has been associated with an increased incidence of positive surgical margins at prostatectomy. 32 As such, patients with an extremely high BMI may not have been included in this patient cohort. Furthermore, a database that is limited to men who have undergone radical prostatectomy is primarily composed of men with localized disease. There are some data indicating that obesity may contribute to a more advanced stage or less differentiated PCa at diagnosis. 3, [36] [37] [38] These patients may be the major contributors to obesity-related PCa and would not have been included in this analysis. It is also important to consider that the gene expression analysis was performed on tumor specimens from prostatectomy samples only. It is possible that obesity affects the normal prostate tissue or the tumor microenvironment, and this leads to increased carcinogenesis or an aggressive phenotype that is not readily detected at a transcriptional level.
It is unclear why these data are inconsistent with prior epidemiological studies indicating that obesity is associated with disease progression in PCa. 39 It is important to note that we did not account for smoking and smoking cessation, factors that have been linked to PCa, cardiovascular, and overall mortality. 40 It is possible that the study was underpowered to detect a difference in PCa outcomes according to BMI. The studies demonstrating an association between BMI and disease progression examined thousands to hundreds of thousands of men, [7] [8] [9] [10] [11] [12] and this may be cost-prohibitive in genomic studies. However, these data suggest that metabolic markers may have a more upstream or intrinsic influence on PCa outcomes than a subsequently elevated BMI. Because the data were generated from a prostatectomy patient cohort with adverse pathological features, it may be that the influence of obesity was outweighed by the impact of positive margins, extraprostatic extension, and seminal vesicle invasion. 41 Their data indicate that a rising BMI trajectory may be more significant to PCa outcomes than stable obesity. This may account for the discrepancy with our study because our assessment of BMI was limited to 1 time point and did not account for its trajectory throughout patients' lives.
In the context of the study's limitations, these data indicate that aberrant metabolic gene expression is correlated with metastases in patients with adverse pathology at the time of prostatectomy. Future studies with more patients may be powered to demonstrate a relation with BMI. Investigators may also examine the disease course of obese men with advanced-stage or metastatic PCa at diagnosis because this may be a population at high risk for PCa mortality.
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